Environmental and genetic determinants of fatty liver in humans

Digestive Diseases

Volumn 28, Issue 1, 2010, Pages 169-178

  Kantartzis, Konstantinos ^a   Schick, Fritz ^a   Häring, Hans Ulrich ^a   Stefan, Norbert ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Department of Internal Medicine IV ^*  (Germany)

Author keywords

DGAT2; Fatty liver; Insulin resistance; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Obesity; PNPLA3; Visceral adipose tissue

Indexed keywords

ACETYLSALICYLIC ACID; ACYL COENZYME A DESATURASE 1; AMIODARONE; COCAINE; DIDANOSINE; DILTIAZEM; ESTROGEN; FATTY ACID; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METHOTREXATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TAMOXIFEN; TETRACYCLINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ZIDOVUDINE;

ABETALIPOPROTEINEMIA; DISEASE ASSOCIATION; ENTERITIS; ENVIRONMENTAL FACTOR; FATTY LIVER; GASTROINTESTINAL SURGERY; GENETIC PREDISPOSITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; INTESTINE DIVERTICULOSIS; LIPID OXIDATION; LIPID STORAGE; LIPODYSTROPHY; LIPOGENESIS; MEDICAL INFORMATION; METABOLIC REGULATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RETINOL INTOXICATION; REVIEW; TOTAL PARENTERAL NUTRITION; WEIGHT REDUCTION;

FATTY ACIDS; FATTY LIVER; HUMANS; LIPID PEROXIDATION; LIVER; MITOCHONDRIA, LIVER; RISK FACTORS; TRIGLYCERIDES;

EID: 77952567958     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000282082     Document Type: Review

References (148)

1. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
2. Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-1219.
3. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ: Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-669.
4. Roden M: Mechanisms of disease: hepatic steatosis in type 2 diabetes - pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006;2:335-348.
5. Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M: Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middleaged Japanese men. Diabetes Care 2007;30:2940-2944.
6. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G: Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005;54:3541-3546.
7. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, Lim SK, Kim KR, Lee HC, Huh KB, Cha BS: Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004;164:2169-2175.
8. Kotronen A, Yki-Jarvinen H: Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:27-38.
9. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G: Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005;42:473-480.
10. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, Balletshofer B, Machicao F, Fritsche A, Haring HU: Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008;168:1609-1616.
11. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395.
12. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL: Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462-E468.
13. Tolman KG, Fonseca V, Dalpiaz A, Tan MH: Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007;30:734-743.
14. Lavine JE, Schwimmer JB: Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis 2004;8:549-558.
15. Nadeau KJ, Klingensmith G, Zeitler P: Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase. J Pediatr Gastroenterol Nutr 2005;41:94-98.
16. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C: Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388-1393.
17. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C, Williams DE, Gregg EW, Bainbridge KE, Saydah SH, Geiss LS: Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009;32:287-294.
18. Nathan BM, Moran A: Metabolic complications of obesity in childhood and adolescence: more than just diabetes. Curr Opin Endocrinol Diabetes Obes 2008;15:21-29.
19. Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, Wong G, Bennett P, Shaw J, Caprio S: The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes 2007;8:299-306.
20. Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, Giani G: High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003;46:182-189.
21. Adams LA, Angulo P, Lindor KD: Nonalcoholic fatty liver disease. CMAJ 2005;172:899-905.
22. Garg A: Acquired and inherited lipodystrophies. N Engl J Med 2004;350:1220-1234.
23. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI: Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002;109:1345-1350.
24. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-1351.
25. Lavoie JM, Gauthier MS: Regulation of fat metabolism in the liver: link to non-alcoholic hepatic steatosis and impact of physical exercise. Cell Mol Life Sci 2006;63:1393-1409.
26. Taskinen MR: Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733-749.
27. Harrison SA, Day CP: Benefits of lifestyle modification in NAFLD. Gut 2007;56:1760-1769.
28. Biddinger SB, Almind K, Miyazaki M, Kokkotou E, Ntambi JM, Kahn CR: Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome. Diabetes 2005;54:1314-1323.
29. Parks EJ, Hellerstein MK: Thematic review series: patient-oriented research. Recent advances in liver triacylglycerol and fatty acid metabolism using stable isotope labeling techniques. J Lipid Res 2006;47:1651-1660.
30. Parks EJ: Dietary carbohydrate's effects on lipogenesis and the relationship of lipogenesis to blood insulin and glucose concentrations. Br J Nutr 2002;87(suppl 2):S247-S253.
31. Diraison F, Moulin P, Beylot M: Contribution of hepatic de novo lipogenesis and re- esterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab 2003;29:478-485.
32. Storlien LH, Higgins JA, Thomas TC, Brown MA, Wang HQ, Huang XF, Else PL: Diet composition and insulin action in animal models. Br J Nutr 2000;83(suppl 1):S85-S90.
33. Clarke SD: Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. Am J Physiol Gastrointest Liver Physiol 2001;281:G865-G869.
34. Sekiya M, Yahagi N, Matsuzaka T, Najima Y, Nakakuki M, Nagai R, Ishibashi S, Osuga J, Yamada N, Shimano H: Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003;38:1529-1539.
35. Hussein O, Grosovski M, Lasri E, Svalb S, Ravid U, Assy N: Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats. World J Gastroenterol 2007;13:361-368.
36. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, Faga E, Silli B, Pagano G: Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37:909-916.
37. Cortez-Pinto H, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME: How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr 2006;25:816-823.
38. Westerbacka J, Lammi K, Hakkinen AM, Rissanen A, Salminen I, Aro A, Yki-Jarvinen H: Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005;90:2804-2809.
39. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI: Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005;54:603-608.
40. Tiikkainen M, Bergholm R, Vehkavaara S, Rissanen A, Hakkinen AM, Tamminen M, Teramo K, Yki-Jarvinen H: Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003;52:701-707.
41. Larson-Meyer DE, Heilbronn LK, Redman LM, Newcomer BR, Frisard MI, Anton S, Smith SR, Alfonso A, Ravussin E: Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 2006;29:1337-1344.
42. Tamura Y, Tanaka Y, Sato F, Choi JB, Watad a H, Niwa M, Kinoshita J, Ooka A, Kumashiro N, Igarashi Y, Kyogoku S, Maehara T, Kawasumi M, Hirose T, Kawamori R: Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005;90:3191-3196.
43. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-1830.
44. Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006;444:860-867.
45. Heilbronn L, Smith SR, Ravussin E: Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord 2004;28(suppl 4):S12-S21.
46. Montague CT, O'Rahilly S: The perils of portliness: causes and consequences of viscera l adiposity. Diabetes 2000;49:883-888.
47. Lebovitz HE, Banerji MA: Point: visceral adiposity is causally related to insulin resistance. Diabetes Care 2005;28:2322-2325.
48. Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Corner A, Bergholm R, Yki-Jarvinen H: Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 2008;31:165-169.
49. Church TS, Kuk JL, Ross R, Priest EL, Biltoft E, Blair SN: Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 2006;130:2023-2030.
50. Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC: Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003;285:E906-E916.
51. Thamer C, Machann J, Haap M, Stefan N, Heller E, Schnodt B, Stumvoll M, Claussen C, Fritsche A, Schick F, Haring H: Intrahepatic lipids are predicted by visceral adipose tissue mass in healthy subjects. Diabetes Care 2004;27:2726-2729.
52. Kantartzis K, Rittig K, Balletshofer B, Machann J, Schick F, Porubska K, Fritsche A, Haring HU, Stefan N: The relationships of plasma adiponectin with a favorable lipid profile, decreased inf lammation, and less ectopic fat accumulation depend on adiposity. Clin Chem 2006;52:1934-1942.
53. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H: Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007;92:3490-3497.
54. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F: Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009;51:433-445.
55. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD: Splanchnic lipolysis in human obesity. J Clin Invest 2004;113:1582-1588.
56. Koutsa ri C, Jensen MD: Thematic review series: patient-oriented research. Free fatty acid metabolism in human obesity. J Lipid Res 2006;47:1643-1650.
57. Tilg H, Kaser A: Treatment strategies in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005;2:148-155.
58. Musso G, Gambino R, Cassader M: Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009;48:1-26.
59. Kim JK: Fat uses a TOLL-road to connect inflammation and diabetes. Cell Metab 2006;4:417-419.
60. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-1119.
61. Morino K, Petersen KF, Shulman GI: Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006;55 (suppl 2):S9-S15.
62. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM: Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998-1003.
63. Memon RA, Grunfeld C, Feingold KR: TNF-alpha is not the cause of fatty liver disease in obese diabetic mice. Nat Med 2001;7:2-3.
64. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE: Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11:183-190.
65. Tilg H, Hotamisligil GS: Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006;131:934-945.
66. Medina J, Fernandez-Salazar LI, Garcia-Buey L, Moreno-Otero R: Approach to the pathogenesis and treatment of nonalcoholic steato-hepatitis. Diabetes Care 2004;27:2057-2066.
67. Iizuka K, Bruick RK, Liang G, Horton JD, Uyeda K: Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci USA 2004;101:7281-7286.
68. Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JR, Girard J, Postic C: Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 2006;55:2159-2170.
69. Minehira K, Vega N, Vidal H, Acheson K, Tappy L: Effect of carbohydrate overfeeding on whole body macronutrient metabolism and expression of lipogenic enzymes in adipose tissue of lean and overweight humans. Int J Obes Relat Metab Disord 2004;28:1291-1298.
70. Le KA, Tappy L: Metabolic effects of fructose. Curr Opin Clin Nutr Metab Care 2006;9:469-475.
71. Yancy WS Jr, Olsen MK, Guyton JR, Bakst RP, Westman EC: A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med 2004;140:769-777.
72. Faeh D, Minehira K, Schwarz JM, Periasamy R, Park S, Tappy L: Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in hea lthy men. Diabetes 2005;54:1907-1913.
73. Elliott SS, Keim NL, Stern JS, Teff K, Havel PJ: Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr 2002;76:911-922.
74. Montminy M, Koo SH: Diabetes: outfoxing insulin resistance? Nature 2004;432:958-959.
75. Brown MS, Goldstein JL: Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 2008;7:95-96.
76. Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H: Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2007;292:E829-E835.
77. Claudel T, Staels B, Kuipers F: The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005;25:2020-2030.
78. Kuipers F, Stroeve JH, Caron S, Staels B: Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. Curr Opin Lipidol 2007;18:289-297.
79. Houten SM, Watanabe M, Auwerx J: Endocrine functions of bile acids. EMBO J 2006;25:1419-1425.
80. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J: Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004;113:1408-1418.
81. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J: Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006;439:484-489.
82. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295.
83. Schimmack G, DeFronzo RA, Musi N: AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes Metab 2006;8:591-602.
84. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.
85. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, Gentilcore E, Natale S, Cassader M, Rizzetto M, Pasquali R, Marchesini G: Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005;90:3498-3504.
86. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307.
87. Stefan N, Machicao F, Staiger H, Machann J, Schick F, Tschritter O, Spieth C, Weigert C, Fritsche A, Stumvoll M, Haring HU: Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia 2005;48:2282-2291. (Pubitemid 41618919)
88. Kantartzis K, Fritsche A, Machicao F, Haring HU, Stefan N: The -8503 G/A polymorphism of the adiponectin receptor 1 gene is associated with insulin sensitivity dependent on adiposity. Diabetes Care 2006;29:464.
89. Despres JP, Lemieux I: Abdominal obesity and metabolic sy ndrome. Nature 2006;444:881-887.
90. Trujillo ME, Scherer PE: Adipose tissue-derived factors: impact on health and disease. Endocr Rev 2006;27:762-778.
91. Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451.
92. Stefan N, Stumvoll M: Adiponectin - its role in metabolism and beyond. Horm Metab Res 2002;34:469-474.
93. Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-2556.
94. Fernandez-Real JM, Ricart W: Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24:278-301.
95. Kantartzis K, Fritsche A, Tschritter O, Thamer C, Haap M, Schafer S, Stumvoll M, Haring HU, Stefan N: The association between plasma adiponectin and insulin sensitivity in humans depends on obesity. Obes Res 2005;13:1683-1691.
96. Mooney RA: Counterpoint: interleukin-6 does not have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 2007;102:816-818.
97. Rabe K, Lehrke M, Parhofer KG, Broedl UC: Adipokines and insulin resistance. Mol Med 2008;14:741-751.
98. Kashyap SR, Diab DL, Baker AR, Yerian L, Bajaj H, Gray-McGuire C, Schauer PR, Gupta M, Feldstein AE, Hazen SL, Stein CM: Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity (Silver Spring) 2009;17:1696-1701.
99. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-E751.
100. Sopasakis VR, Sandqvist M, Gustafson B, Hammarstedt A, Schmelz M, Yang X, Jansson PA, Smith U: High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator. Obes Res 2004;12:454-460.
101. Wei Y, Rector RS, Thyfault JP, Ibdah JA: Nonalcoholic fatty liver disease and mito-chondrial dysfunction. World J Gastroenterol 2008;14:193-199. (Pubitemid 351314298)
102. Toledo FG, Watkins S, Kelley DE: Changes induced by physical activity and weight loss in the morphology of intermyofibrillar mitochondria in obese men and women. J Clin Endocrinol Metab 2006;91:3224-3227.
103. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM: Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003;113:159-170.
104. Stefan N, Thamer C, Staiger H, Machicao F, Machann J, Schick F, Venter C, Niess A, Laakso M, Fritsche A, Haring HU: Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab 2007;92:1827-1833.
105. Thamer C, Machann J, Stefan N, Schafer SA, Machicao F, Staiger H, Laakso M, Bottcher M, Claussen C, Schick F, Fritsche A, Haring HU: Variations in PPARD determine the change in body composition during lifestyle intervention: a whole-body magnetic resonance study. J Clin Endocrinol Metab 2008;93:1497-1500.
106. Lawlor DA, Sattar N, Smith GD, Ebrahim S: The associations of physical activity and adiposity with alanine aminotransferase and gamma- glutamyltransferase. Am J Epidemiol 2005;161:1081-1088.
107. Perseghin G, Lattuada G, De Cobelli F, Ragogna F, Ntali G, Esposito A, Belloni E, Canu T, Terruzzi I, Scifo P, Del Maschio A, Luzi L: Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care 2007;30:683-688.
108. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, Halavaara J, Yki-Jarvinen H: Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023-3028.
109. Nguyen-Duy TB, Nichaman MZ, Church TS, Blair SN, Ross R: Visceral fat and liver fat are independent predictors of metabolic risk factors in men. Am J Physiol Endocrinol Metab 2003;284:E1065-E1071.
110. Kantartzis K, Thamer C, Peter A, Machann J, Schick F, Schraml C, Konigsrainer A, Konigsrainer I, Krober S, Niess A, Fritsche A, Haring HU, Stefan N: High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 2009;58:1281-1288.
111. Szendroedi J, Chmelik M, Schmid AI, Nowotny P, Brehm A, Krssak M, Moser E, Roden M: Abnormal hepatic energy homeostasis in type 2 diabetes. Hepatology 2009;50:1079-1086.
112. Pessayre D, Fromenty B: NASH: a mitochondria l disease. J Hepatol 2005;42:928-940.
113. Ibdah JA, Perlegas P, Zhao Y, Angdisen J, Borgerink H, Shadoan MK, Wagner JD, Matern D, Rinaldo P, Cline JM: Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. Gastroenterology 2005;128:1381-1390.
114. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
115. Miyazaki M, Kim YC, Ntambi JM: A lipogenic diet in mice with a disruption of the stearoyl-CoA desaturase 1 gene reveals a stringent requirement of endogenous monounsaturated fatty acids for triglyceride synthesis. J Lipid Res 2001;42:1018-1024.
116. Peter A, Cegan A, Wagner S, Lehmann R, Stefan N, Konigsrainer A, Konigsrainer I, Haring HU, Schleicher E: Hepatic lipid composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be estimated from plasma VLDL fatty acid ratios. Clin Chem 2009;55:2113-2120.
117. Stefan N, Peter A, Cegan A, Staiger H, Machann J, Schick F, Claussen CD, Fritsche A, Haring HU, Schleicher E: Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans. Diabetologia 2008;51:648-656.
118. Bernard S, Touzet S, Personne I, Lapras V, Bondon PJ, Berthezene F, Moulin P: Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 2000;43:995-999.
119. Stefan N, Schafer S, Machicao F, Machann J, Schick F, Claussen CD, Stumvoll M, Haring HU, Fritsche A: Liver fat and insulin resistance are independently associated with the -514C >T polymorphism of the hepatic lipase gene. J Clin Endocrinol Metab 2005;90:4238-4243. (Pubitemid 41058203)
120. Kantartzis K, Fritsche A, Machicao F, Stumvoll M, Machann J, Schick F, Haring HU, Stefan N: Upstream transcription factor 1 gene polymorphisms are associated with high antilipolytic insulin sensitivity and show gene-gene interactions. J Mol Med 2007;85:55-61.
121. Toledo FG, Sniderman AD, Kelley DE: Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 2006;29:1845-1850.
122. Kantartzis K, Rittig K, Cegan A, Machann J, Schick F, Balletshofer B, Fritsche A, Schleicher E, Haring HU, Stefan N: Fatty liver is independently associated with alterations in circulating HDL2 and HDL3 sub-fractions. Diabetes Care 2008;31:366-368.
123. Kantartzis K, Haring HU, Stefan N: Fatty liver and HDL-cholesterol: just a matter of quantity? Future Lipidol 2008;3:225-227.
124. Auberger P, Falquerho L, Contreres JO, Pages G, Le Cam G, Rossi B, Le Cam A: Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 1989;58:631-640.
125. Rauth G, Poschke O, Fink E, Eulitz M, Tippmer S, Kellerer M, Haring HU, Nawratil P, Haasemann M, Jahnen-Dechent W: The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur J Biochem 1992;204:523-529.
126. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Krober SM, Machicao F, Fritsche A, Haring HU: Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006;29:853-857.
127. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Haring HU, Stefan N: Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One 2008;3:e1765.
128. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Haring HU, Schulze MB: Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008;57:2762-2767.
129. Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, Cauley JA, Harris TB, Cummings SR, Shlipak MG: Fetuin-A and incident diabetes mellitus in older persons. JAMA 2008;300:182-188.
130. Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, Haring HU, Boeing H, Fritsche A: Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008;118:2555-2562.
131. Fisher A, Stefan N, Saar K, Drogan D, Schulze MB, Fritsche A, Joost HG, Haring HU, Huebner N, Boeing,H, Weikert C: Association of AHSG gene polymorphisms with fetuin-A plasma levels and cardiovascular diseases in the EPIC-Potsdam Study. Circ Cardiovasc Genet 2009;2:607-613.
132. Stefan N, Kantartzis K, Haring HU: Causes and metabolic consequences of fatty liver. Endocr Rev 2008;29:939-960.
133. Kantartzis K, Totsikas C, Haring HU, Stefan N: Role of ectopic fat in the pathogenesis of insulin resistance. Clinical Lipidology 2009;4:457-464.
134. Unger RH: Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003;144:5159-5165.
135. Unger RH: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995;44:863-870.
136. Peter A, Weigert C, Staiger H, Machicao F, Schick F, Machann J, Stefan N, Thamer C, Haring HU, Schleicher E: Individual stearoyl-CoA desaturase 1 expression modulates endoplasmic reticulum stress and inflammation in human myotubes and is associated with skeletal muscle lipid storage and insulin sensitivity in vivo. Diabetes 2009;58:1757-1765.
137. Matsuzaka T, Shimano H, Yahagi N, Yoshikawa T, Amemiya-Kudo M, Hasty AH, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Takahashi A, Yato S, Sone H, Ishibashi S, Yamada N: Cloning and characterization of a mammalian fatty acyl-CoA elongase as a lipogenic enzyme regulated by SREBPs. J Lipid Res 2002;43:911-920.
138. Matsuzaka T, Shimano H, Yahagi N, Kato T, Atsumi A, Yamamoto T, Inoue N, Ishikawa M, Okada S, Ishigaki N, Iwasaki H, Iwasaki Y, Karasawa T, Kumadaki S, Matsui T, Sekiya M, Ohashi K, Hasty AH, Nakagawa Y, Takahashi A, Suzuki H, Yatoh S, Sone H, Toyoshima H, Osuga J, Yamada N: Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat Med 2007;13:1193-1202.
139. Buhman KK, Chen HC, Farese RV Jr: The enzymes of neutral lipid synthesis. J Biol Chem 2001;276:40369-40372.
140. Monetti M, Levin MC, Watt MJ, Sajan MP, Marmor S, Hubbard BK, Stevens RD, Bain JR, Newgard CB, Farese RV Sr, Hevener AL, Farese RV Jr: Dissociation of hepatic steatosis and insulin resistance in mice overex- pressing DGAT in the liver. Cell Metab 2007;6:69-78.
141. Kantartzis K, Machicao F, Machann J, Schick F, Fritsche A, Haring HU, Stefan N: The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans. Clin Sci (Lond) 2009;116:531-537.
142. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH: Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-1465.
143. Kotronen A, Johansson LE, Johansson LM, Roos C, Westerbacka J, Hamsten A, Bergholm R, Arkkila P, Arola J, Kiviluoto T, Fisher RM, Ehrenborg E, Orho-Melander M, Ridderstrale M, Groop L, Yki-Jarvinen H: A common variant in PNPLA3, which encodes adiponutr in, is associated with liver fat content in humans. Diabetologia 2009;52:1056-1060.
144. Kantartzis K, Peter A, Machicao F, Machann J, Wagner S, Konigsrainer I, Konigsrainer A, Schick F, Fritsche A, Haring HU, Stefan N: Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009;58:2616-2623.
145. Jenkins CM, Mancuso DJ, Yan W, Sims HF, Gibson B, Gross RW: Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem 2004;279:48968-48975.
146. Lake AC, Sun Y, Li JL, Kim JE, Johnson JW, Li D, Revett T, Shih HH, Liu W, Paulsen JE, Gimeno RE: Expression, regulation, and triglyceride hydrolase activity of adiponutrin family members. J Lipid Res 2005;46:2477-2487.
147. Johansson LE, Lindblad U, Larsson CA, Rastam L, Ridderstrale M: Polymorphisms in the adiponutrin gene are associated with increased insulin secretion and obesity. Eur J Endocrinol 2008;159:577-583.
148. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, Zhang XM, Monia BP, Bhanot S, Shulman GI: Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 2007;117:739-745.